Navigation Links
Cardium Reports on Exchange Listing With NYSE Alternext US
Date:12/30/2008

SAN DIEGO, Dec. 30 /PRNewswire-FirstCall/ -- Cardium Therapeutics (NYSE Alternext US: CXM) reported notification from the staff of its current listing exchange indicating that the company is currently considered to be noncompliant with certain listing requirements of the NYSE Alternext US LLC (formerly the American Stock Exchange). Based on the company's quarterly report on Form 10-Q, which was filed on November 10, 2008, noncompliance was noted with respect to the requirements for minimum stockholders' equity and maintenance of a sufficient base of financial resources to support expected activities, under sections 1003(a)(i) and (iv), respectively, of the exchange's current company guide.

(Logo: http://www.newscom.com/cgi-bin/prnh/20051018/CARDIUMLOGO)

This initial notification has no current effect on the listing of the company's shares on the exchange. Rather, the company has been afforded the opportunity to submit a proposed plan to the exchange by January 23, 2009, pursuant to which the company could establish compliance with the requirements of section 1003(a)(iv) by March 23, 2009, and in compliance with all sections, including section 1003(a)(i), by June 23, 2010. If the company does not submit an acceptable plan to the exchange or does not ultimately reestablish compliance within the required timeframes, then the exchange would be expected to initiate delisting proceedings. If the company's common stock was ultimately delisted from the exchange, it would be expected to trade on the OTC Bulletin Board, a regulated quotation service that provides quotes, sale prices and volume information in over-the-counter equity securities. The company's common stock was traded on the OTC Bulletin Board until July 2007, when the company elected to instead list its shares on the American Stock Exchange.

Abou
'/>"/>

SOURCE Cardium Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine news :

1. An international first at the CHUM - Promising treatment in regeneration of the myocardium through the use of stem cells
2. Cardium Reports on Recent Highlights and Financial Results
3. Cardiums InnerCool Therapies Unit Announces Australian Distribution Agreement for CoolBlue and Rapid Blue Systems
4. Cardium Announces InnerCools Endovascular Cooling to be Featured on Science Channels Series Cool Stuff: How It Works
5. Cardium Completes $6.0 Million Financing
6. Cardium Announces Investor Presentation and Corporate Update Webcast
7. Cardium Reports on New York Citys Adoption of Therapeutic Cooling Protocols for Cardiac Arrest Patients
8. New Study Reports High Injury Rates for Hotel Workers, Even Higher Rates for Women and Nonwhites
9. Haemacure Reports Third Quarter 2007 Results
10. First-Ever List of the 5,000 Fastest-Growing Businesses Reports Total Revenue of $194.5 Billion
11. Consumer Reports Analysis: Drugs for Nerve Pain, Fibromyalgia Effective, But Not Always Best
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/4/2015)... ... ... Dating a real millionaire online can be more difficult. Millionairematchapp.com ... to remove the worries from meeting partners. Recently, the site announced they're publishing ... and readers have responded with excitement. , “There's quite a few millionaire dating ...
(Date:7/4/2015)... ... ... When a hacker gains access to someone’s email account, it can lead to all sorts ... the FTC issued a scam alert about a social engineering scam which cons ... reset instigated by the hacker. All they have to do is click for a ...
(Date:7/3/2015)... ... July 03, 2015 , ... Brendon Burchard's new ... buzz of media attention. In an effort to spread the news, a comprehensive ... "These days many people are feeling overwhelmed by stress and fatigue," reports Hendricks. ...
(Date:7/3/2015)... ... July 03, 2015 , ... Scientists at several top ... mesothelioma with even minimal asbestos exposure. Click here to read the complete story ... of Hawaii Cancer Center, Cedars Sinai Medical Center, and New York University exposed mice ...
(Date:7/3/2015)... ... July 03, 2015 , ... B. E. ... been retained to lead a national chief nursing officer recruitment for ... firms in the healthcare industry, B. E. Smith has recently placed more than ...
Breaking Medicine News(10 mins):Health News:MillionaireMatchapp.com Publishes the Best Millionaire Dating App and Official Dating Site Reviews 2015 2Health News:New FTC Scam Alert Shows Latest Example of Social Engineering Dangers 2Health News:New FTC Scam Alert Shows Latest Example of Social Engineering Dangers 3Health News:New FTC Scam Alert Shows Latest Example of Social Engineering Dangers 4Health News:High Performance Academy - Review Of Brendon Burchard's New High Performance Training Program Released 2Health News:High Performance Academy - Review Of Brendon Burchard's New High Performance Training Program Released 3Health News:Study Finds Small Amounts of Asbestos May Trigger Mesothelioma in People with Genetic Mutation, According to Surviving Mesothelioma 2Health News:Jane Phillips Medical Center Retains B. E. Smith to Recruit New Chief Nursing Officer 2Health News:Jane Phillips Medical Center Retains B. E. Smith to Recruit New Chief Nursing Officer 3
... method to diagnose lung disease that is based on the ... led a team of researchers in using a sensor employed ... ,The sensor, called a microDMxTM sensor was developed ... detect "unhealthy" molecules emanating from the breath of a patient. ...
... of Quinolone antibiotics for eardrum perforations has been ... disease than the use of systemic antibiotics//. Dr. ... in the Liverpool School of Tropical Medicine, UK ... Cochrane Library that topical quinolone are better than ...
... aspirin to prevent heart problem have increased tremendously//. ... of Public Health (GSPH) and others conducted the study and ... African Americans and diabetics do not opt for aspirin therapy. ... and Europe measured regular use of aspirin among 2,163 African ...
... Griffiths, Ph.D., professor of geriatric medicine, University of Pittsburgh School ... the reduced activity of the orbitofrontal cortex of the brain. ... issue of the Journal of Urology. He studied the brain ... He analyzed the brain activity of 6 normal people and ...
... of breast cancer cases in the UK. As many as ... ductal carcinoma// in situ (DCIS) during 2002. The Cancer Research ... therapy drugs are capable of preventing the recurrence of the ... being studied. The DCIS is considered a pre-cancerous condition, which ...
... fertility kit, which is termed as the Plan Ahead kit comes ... and helps them to decide about their pregnancy//. The kit ... completing all the necessary tests. It gives them a clear view ... and compares it with a standard levels. The results help the ...
Cached Medicine News:Health News:Sensor Can Detect "Unhealthy" Molecules In Breath 2Health News:New fertility kit, analyzes the woman's ability to conceive 2
(Date:7/6/2015)... , July 6, 2015 Akcea ... (NASDAQ: ISIS ), announced today that the ... Drug Designation to volanesorsen (ISIS-APOCIII Rx ) for ... (FCS).  FCS is a rare genetic disease characterized ... pancreatitis. In a Phase 2 study published in ...
(Date:7/5/2015)... , July 6, 2015 Nihon University ... symposium on Medical-Engineering Collaboration "Medicine Definitely Jumps ... 10, 2015 in Tokyo, Japan ... medical applied research will present their achievements and ... a new industry produced with 8K technology. ...
(Date:7/3/2015)... MUMBAI, India , July 4, 2015 /PRNewswire/ ... médicale continue cible les épidémies que sont l,hypertension, ... centrale et du Sud-Est, par l,intermédiaire de plateformes ... ces maladies.      (Photo: http://photos.prnewswire.com/prnh/20150630/227090 ... Prendre en charge le diabète en ligne , ...
Breaking Medicine Technology:Akcea Therapeutics Receives Orphan Drug Designation from the US FDA for Volanesorsen (ISIS-APOCIII Rx) for the Treatment of Familial Chylomicronemia Syndrome 2Akcea Therapeutics Receives Orphan Drug Designation from the US FDA for Volanesorsen (ISIS-APOCIII Rx) for the Treatment of Familial Chylomicronemia Syndrome 3Akcea Therapeutics Receives Orphan Drug Designation from the US FDA for Volanesorsen (ISIS-APOCIII Rx) for the Treatment of Familial Chylomicronemia Syndrome 4Akcea Therapeutics Receives Orphan Drug Designation from the US FDA for Volanesorsen (ISIS-APOCIII Rx) for the Treatment of Familial Chylomicronemia Syndrome 5Akcea Therapeutics Receives Orphan Drug Designation from the US FDA for Volanesorsen (ISIS-APOCIII Rx) for the Treatment of Familial Chylomicronemia Syndrome 6Nihon University to Host International Symposium on Medical-Engineering Collaboration 2Nihon University to Host International Symposium on Medical-Engineering Collaboration 3Lutter contre trois maladies chroniques majeures en Asie centrale et du Sud-Est grâce à la formation médicale 2Lutter contre trois maladies chroniques majeures en Asie centrale et du Sud-Est grâce à la formation médicale 3
... Aug. 24 Curemark Founder and CEO Dr. Joan Fallon ... Sequencing 2009 Conference at Harvard Medical School on July 14th. ... this cutting-edge conclave is particularly significant, since epigenetics is the ... a change in the DNA sequence. Presenters at the session ...
... , EMERYVILLE, Calif., Aug. 21 ... NBY ), a clinical stage company developing non-antibiotic anti-infective compounds ... viral, and fungal infections, will deliver two poster presentations at the ... San Francisco, CA. The two poster presentations will describe results ...
Cached Medicine Technology:Curemark CEO Presents at Epigenomics Conference 2NovaBay Pharmaceuticals to Present New Data on Lead Anti-Infective Compound at the 2009 ICAAC Annual Meeting 2NovaBay Pharmaceuticals to Present New Data on Lead Anti-Infective Compound at the 2009 ICAAC Annual Meeting 3
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: